Drug Development in Dementia


From bench to bedside, drug development is the process of bringing a novel drug to market. As a progressive and irreversible decline in cognition, dementia affects a patient's pre-existing level of functioning, according to its definition. Alzheimer's disease (AD) is the most common cause of the clinical syndrome of dementia. In Alzheimer's disease, drug development is based on pathophysiological theory that is constantly evolving.


  • Discovery & Development
  • Preclinical Research
  • Clinical Development
  • Post-market Monitoring

Related Conference of Drug Development in Dementia

April 24-25, 2025

6th World Congress on Sleep Disorders and Therapeutics

Amsterdam, Netherlands
April 29-30, 2025

11th International Conference on Epilepsy & Treatment

Barcelona, Spain
May 12-13, 2025

39th European Neurology Congress

London, UK
July 17-18, 2025

31st Annual Summit on Neuroscience & Neurological Disorders

Amsterdam, Netherlands
July 23-24, 2025

15th Global Alzheimers Summit

Paris, France
July 28-29, 2025

35th World Congress on Neurology and Neuroscience

Paris, France
August 25-26, 2025

20th Annual Congress on Neuroscience

Aix-en-Provence, France
September 04-05, 2025

10th Annual Neurologists and Neurosurgeons Meet

Vancouver, Canada
September 25-26, 2025

12th Annual congress on Stroke and Neurological Disorders

Zurich, Switzerland
October 20-21, 2025

7th World Brain Congress

Osaka, Japan
October 23-24, 2025

8th Global Congress on Spine and Spinal Disorders

London, UK
October 29-30, 2025

5th Annual Dementia Congress

Amsterdam, Netherlands
November 13-14, 2025

32nd Cognitive Neuroscience Congress

Bali, Indonesia
December 04-05, 2025

17th Global Neurologists Meeting on Neurology and Neurosurgery

Amsterdam, Netherlands

Drug Development in Dementia Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in